Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
3 Ways to Invest in the Growing GLP-1 Weight Loss Market MarketBeat - Fri Apr 17, 10:20AM CDT

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

NVO : 39.15 (-0.68%)
OZEM : 31.48 (+0.51%)
LLY : 921.48 (+2.04%)
GPCR : 46.50 (-0.70%)
THNR : 24.47 (+0.38%)
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel GlobeNewswire - Tue Apr 14, 3:05PM CDT

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 46.50 (-0.70%)
MarketBeat.com
3 Companies at the Forefront of the GLP-1 Pill Wars MarketBeat - Mon Mar 16, 6:44AM CDT

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

VKTX : 34.25 (+1.33%)
LLY : 921.48 (+2.04%)
GPCR : 46.50 (-0.70%)
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GlobeNewswire - Mon Mar 16, 6:00AM CDT

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral...

GPCR : 46.50 (-0.70%)
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights GlobeNewswire - Thu Feb 26, 3:02PM CST

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS...

GPCR : 46.50 (-0.70%)
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity GlobeNewswire - Wed Dec 17, 2025

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 46.50 (-0.70%)
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs GlobeNewswire - Thu Dec 11, 2025

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 46.50 (-0.70%)
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants GlobeNewswire - Tue Dec 9, 2025

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 46.50 (-0.70%)
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants GlobeNewswire - Mon Dec 8, 2025

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 46.50 (-0.70%)
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GlobeNewswire - Mon Dec 8, 2025

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight...

GPCR : 46.50 (-0.70%)

Barchart Exclusives

This Dividend Stock Keeps Hitting It Out of the Park: Should You Buy? Barchart - 4 minutes ago
Citigroup's financial performance has been impressive over the last couple of years as its transformation under CEO Jane Fraser is bearing fruit. Is the stock a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.